Loading company…
Outpace Bio develops engineered cell therapies for cancer treatment.
Founded in 2020 and based in Seattle, US, Outpace Bio develops engineered cell therapies using protein design technologies to address challenges in solid tumor treatment. It works with biopharmaceutical companies and research institutions. The company raised USD 56.00 mn in a Series B round on July 17, 2024, led by RA Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in